Insider Selling: Annexon, Inc. (NASDAQ:ANNX) CEO Sells $14,811.95 in Stock

Annexon, Inc. (NASDAQ:ANNX) CEO Douglas Love sold 5,021 shares of Annexon stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $2.95, for a total transaction of $14,811.95. Following the transaction, the chief executive officer now owns 351,554 shares in the company, valued at $1,037,084.30. The trade was a 1.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Annexon Price Performance

NASDAQ:ANNX opened at $2.83 on Friday. The firm has a 50-day moving average of $4.29 and a two-hundred day moving average of $5.57. The stock has a market cap of $301.66 million, a P/E ratio of -2.70 and a beta of 1.07. Annexon, Inc. has a 1-year low of $2.63 and a 1-year high of $8.40.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ANNX. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Annexon during the 4th quarter worth approximately $252,000. TFG Asset Management GP Ltd grew its position in shares of Annexon by 78.5% during the fourth quarter. TFG Asset Management GP Ltd now owns 1,400,000 shares of the company’s stock worth $7,182,000 after buying an additional 615,645 shares in the last quarter. Shay Capital LLC bought a new stake in shares of Annexon in the fourth quarter worth $159,000. Sphera Funds Management LTD. bought a new stake in shares of Annexon in the fourth quarter worth $6,377,000. Finally, Rafferty Asset Management LLC raised its holdings in Annexon by 23.5% in the fourth quarter. Rafferty Asset Management LLC now owns 218,369 shares of the company’s stock valued at $1,120,000 after acquiring an additional 41,544 shares in the last quarter.

Analysts Set New Price Targets

Several research firms have commented on ANNX. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 target price on shares of Annexon in a research note on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Annexon in a research report on Tuesday, December 17th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Annexon has a consensus rating of “Buy” and an average target price of $15.80.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.